NovoBiome and INRAE: a new Associated Partner Laboratory on human gut microbiota

This is a new partnership to aggregate cutting-edge technologies to study host-microbiota relationships as closely as possible to human physiology.
It confirms INRAE's commitment to develop and enhance the excellence of the research carried out by the institute.

Published on 24 June 2021

illustration NovoBiome and INRAE: a new Associated Partner Laboratory on human gut microbiota

NovoBiome ("the Company"), a drug discovery company developing breakthrough Live Biotherapeutics Products (LBPs)[1] targeting the microbiome-gut-liver axis, is building NovoSift®, a disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.

INRAE, and in particular the MetaGenoPolis unit (MGP), has a world-renowned expertise and an in-depth knowledge of the metagenomics of the intestinal microbiota. MGP has developed a unique know-how on high-throughput functional metagenomics. NovoBiome and INRAE have entered into a partnership to develop a new functional metagenomic approach using innovative reporter systems based on human intestinal organoids, and allowing to measure the impact of interactions between the microbiota and the host on intestinal permeability in the presence or absence of substrates of interest (molecules, probiotics, prebiotics or foods) and using confocal microscopy and artificial intelligence.

For INRAE, this is the second agreement of this new kind of agile partnership aimed at accelerating the development of innovations. Co-constructed by NovoBiome and MGP, the NovoSift® platform project will enable the pooling of human and material resources over a period of 5 years in order to upgrade the paradigms of ex vivo studies.


The NovoSift® platform aims at becoming a true Rosetta stone of host-microbiota interactions.

Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: "Next-generation sequencing and quantitative metagenomics approaches have allowed the reconstruction of whole genomic entities. Then, functional metagenomics has allowed access to the potential of bacterial genes of the whole gut microbiota. Now we need to understand how these functions are regulated in the host-microbiota relationship. To make a linguistic analogy, after words and syntax, the NovoSift® platform aims at deciphering the semantics and becoming a true Rosetta stone of these critical interactions. The MGP unit has not only been a pioneer but also remains at the forefront of world research in this field. It is therefore a privilege for NovoBiome to be able to count on this excellent partnership."

A new type of partnership that is flexible and mutually beneficial for both entities.

“INRAE is proud to see the emergence of start-ups such as NovoBiome, which enhance the excellent academic work initiated by INRAE researchers. Our strong commitment to support these initiatives has prevailed in the design of a new type of partnership that is flexible and mutually beneficial for both entities. The shared objective is performance but also efficiency in speeding up the implementation of new concepts.” commented Philippe Lénée, Director of Partnership and Transfer for Innovation at INRAE.


[1] LBPs are medicinal products containing living micro-organisms such as bacteria or yeasts, which have a positive influence on the health and physiology of the host. Source: Ph. Eur. Monograph 3053 (EDQM, 2019)


Novobiome Metagenopolis INRAE


Joint laboratories at the heart of INRAE's innovation policy
This new form of partnership has several advantages for INRAE and its partner. For INRAE, it will allow the emergence of new research topics and possible access to certain equipment, skills or data from its socio-economic partners. For the partner, it represents access to scientific excellence, to state-of-the-art equipment and to differentiation and competitiveness through innovation. For both partners, the results of the work could lead to publications, separately or jointly depending on the subject, but also to joint development, in particular by filing a patent.


Anne-Sophie ALVAREZ Microbiome communication ManagerMetaGenoPolis unit

Pierre-Yves Mousset Chief Executive OfficerNovoBiome

Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs Consilium Strategic Communications



Learn more

Food, Global Health

Durable changes in the intestinal ecosystem: new perspectives for the treatment of chronic inflammatory diseases

PRESS RELEASE - Crohn's disease, ulcerative colitis, obesity, diabetes, liver diseases, Parkinson's disease, Alzheimer’s disease, autism and cardiovascular diseases are all chronic disorders whose prevalence has increased markedly over the past 60 years. Most of them are associated with a loss of diversity and changes in the microbiota. A balanced dialogue between a human being (the host) and its intestinal microbiota is essential to maintaining good health. Based on an animal model, scientists have proved for the first time that intestinal inflammation and concomitant changes in the microbiota can mutually sustain each other and generate a stable pre-disease state. They were thus able to show that the simple induction of inflammation can durably alter host-microbiota symbiosis, preventing a return to normal even 40 days after the trigger had been removed. Their results, obtained within the framework of the European ERC project Homo symbiosus coordinated by INRAE, were published on 6 October in Microbiome. They open new perspectives in terms of diagnosis, preventive nutrition and therapy in medicine.

23 October 2020